Open Orphan PLC Change of name to hVIVO plc effective (9466D)

TIDMORPH

RNS Number : 9466D

Open Orphan PLC

25 October 2022

Open Orphan plc

("Open Orphan" or the "Company")

Change of name to hVIVO plc

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that further to its announcement on 8 September 2022 , the Company's change of name to hVIVO plc (AIM: HVO) has now been completed and is expected to take effect on AIM and Euronext Growth from 8.00 am tomorrow.

The Company's ticker will be HVO and the website address (including the investor relations content and the information required by AIM Rule 26 and Euronext Growth Rule 3.4) will be available at www.hvivo.com .

The Company's ISIN (GB00B9275X97) and SEDOL (B9275X9) will remain the same.

Shareholders will be unaffected by the change of name and existing share certificates should be retained and will remain valid. Any new share certificates issued after the name change takes effect will bear the name hVIVO plc.

For further information please contact:

 
 Open Orphan plc                                                     [phone] 
 Yamin Khan, Chief Executive Officer 
 
 Liberum Capital (Nominated Adviser 
  and Joint Broker)                                                  [phone] 
 Ben Cryer/ Edward Mansfield/ Phil 
  Walker/ Will King 
 
 finnCap plc (Joint Broker)                                          [phone] 
 Geoff Nash / James Thompson / Nigel 
  Birks 
 
 Davy (Euronext Growth Adviser and 
  Joint Broker)                                                       [phone] 
 Anthony Farrell 
 
 Walbrook PR (Financial PR & IR)         [phone] or [e-mail] 
  Stephanie Cuthbert / Phillip                    [phone] / [phone] 
  Marriage /                                                                        082 / 
  Louis Ashe-Jepson                                                  [phone] 
 
 

Notes to Editors

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CANBKQBBCBDDOKB

(END) Dow Jones Newswires

October 25, 2022 02:00 ET (06:00 GMT)